Neuroendocrine Tumors (NETs)
A diverse group of tumors arising from hormone-producing neuroendocrine cells, most often in the gastrointestinal tract, pancreas, or lung, ranging from slow-growing to more aggressive forms.
- Grade and biomarker-based classification
- Somatostatin receptor imaging
- Access to PRRT and targeted therapies
- Most Common In
- GI Tract, Pancreas, Lung
- Key Test
- Ki-67 Index / Somatostatin Imaging
- Grading System
- WHO Grade 1โ3
- Common Marker
- Chromogranin A
- Advanced Therapies
- PRRT, Somatostatin Analogs, Trials
Condition Overview
Neuroendocrine tumors (NETs) develop from neuroendocrine cells found throughout the body, most commonly in the gastrointestinal tract, pancreas, and lungs. These tumors range from slow-growing, well-differentiated forms to more aggressive, poorly differentiated neuroendocrine carcinomas, and some produce excess hormones that cause distinct symptom patterns.
Types and Subtypes
NETs are classified by grade, differentiation, site of origin, and hormonal activity.
Symptoms and Signs
Many NETs are discovered incidentally, while functional tumors can cause distinct hormone-related symptoms.
Causes and Risk Factors
Most NETs occur sporadically, though certain inherited syndromes increase risk.
Diagnosis and Investigations
Diagnosis combines tissue biopsy, biomarker testing, and specialized imaging to confirm the tumor type, grade, and extent.
Staging and Risk Groups
NETs are staged using site-specific TNM systems, while grade (based on Ki-67 and mitotic count) is used alongside stage to assess risk.
Standard Treatment
Treatment depends heavily on tumor grade, location, and whether disease is localized or metastatic.
Advanced & Emerging Therapies
Targeted and receptor-based therapies have substantially expanded options for advanced NETs.
Radioligand Therapy
Peptide Receptor Radionuclide Therapy (PRRT)
Delivers targeted radiation to somatostatin receptor-positive tumors, approved for progressive gastroenteropancreatic NETs.
Targeted Therapy
mTOR inhibitors
Used in advanced pancreatic and certain other NETs to slow tumor growth.
Targeted Therapy
Tyrosine kinase inhibitors
Considered for select advanced pancreatic NETs.
Investigational Agent
Next-generation radioligand and combination therapies
Being studied in trials to improve outcomes in higher-grade or PRRT-resistant disease.
Biomarkers & Precision Medicine
Biomarker and receptor status testing guide both diagnosis and treatment selection in NETs.
When to Seek 2nd Opinion
Given the diversity of NET subtypes and the specialized nature of treatments such as PRRT, a second opinion can be especially valuable.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in NETs varies widely, often more favorable than other cancers at a similar stage, but strongly influenced by grade and differentiation.
Supportive Care
Supportive care in NETs often focuses on managing hormone-related symptoms alongside cancer-directed treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps you organize your pathology, Ki-67, and somatostatin receptor imaging results to clarify your NET grade and explore PRRT or other targeted treatment options.
Get a free case reviewFrequently Asked Questions
NETs are tumors that arise from hormone-producing neuroendocrine cells, most commonly in the gastrointestinal tract, pancreas, or lung, and range from slow-growing to more aggressive forms.
Many NETs are found incidentally, but functional tumors can cause flushing, chronic diarrhea, abdominal pain, or symptoms of low blood sugar.
Carcinoid syndrome refers to flushing, diarrhea, and other symptoms caused by hormone substances released by certain functional gastrointestinal NETs, usually once the tumor has spread to the liver.
NETs are graded as G1, G2, or G3 based on the Ki-67 proliferation index and mitotic count, which reflects how quickly the tumor is growing.
Peptide Receptor Radionuclide Therapy (PRRT) is a targeted radioactive treatment for somatostatin receptor-positive NETs, typically used for progressive or metastatic disease.
Surgical resection can be curative for many localized, low-grade NETs, though some tumors are diagnosed at a more advanced stage requiring systemic therapy.
Well-differentiated NETs tend to grow more slowly, while poorly differentiated neuroendocrine carcinomas behave more aggressively and are often treated more like other high-grade cancers.
Yes, particularly when there is a family history or multiple tumors, since syndromes such as MEN1 or Von Hippel-Lindau can be associated with NET development.
Monitoring typically includes periodic imaging, such as somatostatin receptor PET, along with blood markers like chromogranin A, tailored to the individual case.
Yes. CancerFax can help you organize your pathology, Ki-67, and somatostatin receptor imaging reports for expert review, support a second opinion request, and help identify PRRT, targeted therapy, or clinical trial options, including coordination with specialists internationally.
Take the Next Step in Your NET Care
Send your pathology and imaging reports to CancerFax for a structured review of your NET grade and treatment options.